Equities
Health CarePharmaceuticals and Biotechnology
  • Price (USD)4.34
  • Today's Change0.110 / 2.60%
  • Shares traded1.80k
  • 1 Year change+21.57%
  • Beta1.2261
Data delayed at least 15 minutes, as of Sep 18 2024 20:32 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Genfit SA is a France-based biopharmaceutical company focused on the discovery and development of therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, particularly due to a lack of approved treatments. The Company provides therapeutic and diagnostic solutions for rare and serious liver diseases , with a particular interest in diseases with largely unmet medical needs. Its laboratory capabilities include pharmacology, molecular and cellular biology, drug candidate screening, medicinal and analytical chemistry, biochemistry, omics analyses, and data science. Its in-house biobank allows to have unparalleled control and precision in the handling and preservation of biological samples, which is crucial to research. The Company leverage artificial intelligence (image processing tools and language models) to create tools that accelerate daily work and decision-making.

  • Revenue in USD (TTM)42.42m
  • Net income in USD-32.11m
  • Incorporated1999
  • Employees159.00
  • Location
    Genfit SAParc Eurasante 885 avenue Eugene AvineeLOOS 59120FranceFRA
  • Phone+33 320164000
  • Fax+33 320164001
  • Websitehttps://www.genfit.fr/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Gossamer Bio Inc95.84m-80.85m203.31m135.00--2.49--2.12-0.3996-0.39960.4340.36040.3453----709,940.80-29.13-57.43-34.41-64.38-----84.36-----7.070.7073------21.61------
CytoDyn Inc0.00-51.32m204.10m9.00---------0.0527-0.05270.00-0.11030.00----0.00-444.45-259.15-----------232,918.20---2.76--------35.70------
Cabaletta Bio Inc0.00-89.98m204.68m136.00--1.01-----1.92-1.920.004.130.00----0.00-44.76-33.76-47.90-35.68------------0.00-------27.75------
Vaxart Inc13.93m-75.66m210.27m109.00--2.63--15.10-0.4707-0.47070.08610.35180.1178--5.80127,779.80-64.01-49.60-73.18-54.86-----543.21-1,398.00---226.730.0507--6,796.2612.1523.47--21.49--
MacroGenics Inc41.02m-136.37m211.06m339.00--3.65--5.15-2.19-2.190.65830.92180.16196.626.51120,997.00-53.82-37.76-67.56-45.5379.37---332.47-133.962.69-172.620.00---61.33-0.460692.44---41.13--
Pyxis Oncology Inc16.15m-59.20m212.78m51.00--1.25--13.18-1.26-1.260.32692.880.0842----322,920.00-30.87---33.12--97.06---366.67------0.0008------38.87------
Genfit SA (ADR)42.42m-32.11m215.98m159.00--2.79--5.09-0.6461-0.64610.85361.520.1961542.003.52266,822.90-14.84-12.57-18.55-15.3094.3294.96-75.69-76.232.94-7.780.5080--43.7038.49-21.82---3.27--
Fulcrum Therapeutics Inc81.63m-20.23m217.78m76.00--0.7935--2.67-0.3507-0.35071.314.400.2746--29.131,074,079.00-6.81-50.55-7.14-55.91-----24.79-1,189.10----0.00---55.77--11.41---43.70--
Codexis Inc60.89m-76.36m224.13m174.00--3.65--3.68-1.09-1.090.87230.86650.35956.273.58349,942.50-45.08-17.13-56.05-20.2377.9577.29-125.41-37.042.92--0.3158---49.392.97-126.96--9.80--
XBiotech Inc0.00-35.01m225.12m94.00--1.14-----1.15-1.150.006.460.00----0.00-15.5331.88-16.3233.27------877.30----0.04840.00-100.00--25.36--24.30--
Candel Therapeutics Inc0.00-49.99m225.40m42.00---------1.70-1.700.00-0.3210.00----0.00-117.35---158.61-------------32.702.36---100.00---101.87------
Compass Therapeutics Inc.850.00k-47.24m228.40m32.00--1.56--268.70-0.3573-0.35730.00641.060.0051----26,562.50-28.22-41.75-29.94-46.41-----5,557.88------0.00-------8.33---56.91--
Omeros Corp0.00-199.92m231.79m198.00---------3.32-2.350.00-2.150.00----0.00-45.24-55.51-58.74-70.10-----------5.741.42------3.91---5.56--
Acrivon Therapeutics Inc0.00-69.00m235.39m58.00--1.09-----2.77-2.770.006.980.00----0.00-35.33---37.06--------------0.00-------93.76------
Data as of Sep 18 2024. Currency figures normalised to Genfit SA's reporting currency: US Dollar USD

Institutional shareholders

0.10%Per cent of shares held by top holders
HolderShares% Held
Morgan Stanley & Co. International Plcas of 30 Jun 202432.46k0.07%
Old Mission Capital LLCas of 30 Jun 202412.82k0.03%
Optiver US LLCas of 30 Jun 20242.24k0.00%
RhumbLine Advisers LPas of 30 Jun 2024678.000.00%
UBS Securities LLCas of 30 Jun 2024346.000.00%
Morgan Stanley Smith Barney LLC (Investment Management)as of 30 Jun 2024300.000.00%
Osaic Fa, Inc. (Investment Management)as of 30 Jun 2024273.000.00%
Qube Research & Technologies Ltd.as of 30 Jun 202498.000.00%
Millennium Management LLCas of 30 Jun 20240.000.00%
Citadel Securities LLCas of 30 Jun 20240.000.00%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.